BTIG raises Medtronic stock price target to $100 on strong results

Medtronic raised fiscal 2027 guidance after beating Q1 FY2027 estimates: revenue rose 13.7% YoY to $9.756B vs $9.458B (BTIG) and adjusted EPS climbed 14.7% YoY to $1.45 vs $1.37. Organic revenue growth guidance increases to 7.25%–7.75% (from 6.75%–7.25%), implying ~$38.9B–$39.2B, while EPS is guided to $5.94–$6.00. BTIG lifted its price target to $100 (from $91) and kept a Buy rating, citing undervaluation versus fair value near the current ~$92.40 price.

Analysis

The immediate winner is MDT’s own multiple: a clean execution print plus a higher guide should support a near-term rerating, but the market should not pay full credit for the headline growth rate because part of the quarter was a calendar pull-forward that will reverse next quarter. The better signal is that several core franchises are now behaving like durable mid-to-high single-digit growers, which matters more for valuation than one quarter of outsized reported growth. That makes MDT a relative safe haven if rates keep moving up and the tape stays defensive.

Second-order, stronger cardiovascular and robotic spend raises competitive pressure on BSX, ISRG, and to a lesser extent SYK/EW in procedure-adjacent categories. If MDT is gaining confidence to invest in Cornerstone and adjacent platforms, the strategic message is that management sees enough cash-generation to compete for share rather than just defend margins. That can compress the multiple gap versus faster growers if the street starts valuing execution consistency over pure top-line growth.

The contrarian risk is that investors may overreact to the beat while underweighting the harder second quarter comp and the fact that the new target already sits near fair value. If the next print normalizes to a lower growth rate, the stock can give back a good portion of the initial move even if the full-year guide stays intact. I would treat any gap-up above the new target as vulnerable to digestion unless management proves the raised guide is conservative via margin expansion and sustained procedure growth.

Key Decisions for Investors

• Buy MDT on post-earnings pullbacks rather than chasing strength; use a 1-3 month horizon, with upside to the low $100s if the market believes the raised guide is repeatable. Falsifier: Q2 organic growth or EPS guide slows materially from the new range.
• Pair trade: long MDT / short BSX for 1-3 months to isolate execution quality versus premium-multiple cardiovascular exposure. The thesis works if MDT’s share gains in ablation and related categories are viewed as durable; it breaks if BSX reaccelerates on its next catalyst.
• If MDT trades above the new fair-value band on the open, consider trimming into strength or using a covered-call overlay instead of adding outright. The near-term upside is more limited than the headline beat suggests because the extra selling week will make the next quarter look softer.
• Set an alert for gross margin and operating margin follow-through over the next two prints; if incremental margins stop improving, the rerating case weakens quickly even if revenue stays above plan.